BMX and neuroblastoma: Altogether, our observations indicate that BMX inhibition could offer a relevant antitumor strategy for patients with HR-NB, with limited on-target toxicity given the modest phenotype displayed by murine KO models (65), and may be particularly efficient in combination with other targeted therapies aiming at eradicating the distinct cell states that participate in the emergence of therapeutic resistance and compose the ecosystem of metastatic NB tumors.